GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transcenta Holding Ltd (HKSE:06628) » Definitions » Revenue

Transcenta Holding (HKSE:06628) Revenue : HK$58.90 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Transcenta Holding Revenue?

Transcenta Holding's revenue for the six months ended in Dec. 2023 was HK$19.43 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$58.90 Mil. Transcenta Holding's Revenue per Share for the six months ended in Dec. 2023 was HK$0.05. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.15.

Warning Sign:

Transcenta Holding Ltd revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Transcenta Holding was -44.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was -12.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 5 years, Transcenta Holding's highest 3-Year average Revenue per Share Growth Rate was 33.70% per year. The lowest was -12.40% per year. And the median was 10.65% per year.


Transcenta Holding Revenue Historical Data

The historical data trend for Transcenta Holding's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transcenta Holding Revenue Chart

Transcenta Holding Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
49.12 96.00 61.52 113.78 58.90

Transcenta Holding Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Revenue Get a 7-Day Free Trial Premium Member Only 28.85 25.51 89.49 39.47 19.43

Competitive Comparison of Transcenta Holding's Revenue

For the Biotechnology subindustry, Transcenta Holding's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Transcenta Holding's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transcenta Holding's Revenue distribution charts can be found below:

* The bar in red indicates where Transcenta Holding's Revenue falls into.



Transcenta Holding Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$58.90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Transcenta Holding  (HKSE:06628) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Transcenta Holding Revenue Related Terms

Thank you for viewing the detailed overview of Transcenta Holding's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Transcenta Holding (HKSE:06628) Business Description

Traded in Other Exchanges
N/A
Address
B6-501, 218 Xinghu Street, Biobay, Suzhou, CHN, 215123
Transcenta Holding Ltd is a clinical stage biopharmaceutical company with fully integrated capacities in discovery, research, development and manufacturing. It is developing nine therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders. Geographically the company operates in China (the "PRC") and the USA.
Executives
Qian Xueming 2101 Beneficial owner
Shi Xiaohong 2501 Other
Lav Corporate Gp, Ltd. 2201 Interest of corporation controlled by you
Lav Gp Iii, L.p. 2201 Interest of corporation controlled by you
Lav Biosciences Fund Iii, L.p. 2101 Beneficial owner
Shi Yi 2201 Interest of corporation controlled by you
Lav Asset Management (hong Kong) Limited 2102 Investment manager
Fullerton Management Pte Ltd
Temasek Life Sciences Private Limited
Tls Beta Pte. Ltd.
Hsbc Trust Company (delaware), N.a. 2301 Trustee
Success Link International L.p. 2101 Beneficial owner
Temasek Holdings (private) Limited
Lav Vitality Limited 2101 Beneficial owner
Zhong Guo Guo You Qi Ye Jie Gou Tiao Zheng Ji Jin Gu Fen You Xian Gong Si 2501 Other

Transcenta Holding (HKSE:06628) Headlines

No Headlines